Clinical Usefulness of a Multigene Testing in Patients with Special Histologic Type Breast Cancer.

IF 2.8 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Suk Jun Lee, Jung Min Park, Jee Hyun Ahn, Chan Seok Yoon, Seho Park
{"title":"Clinical Usefulness of a Multigene Testing in Patients with Special Histologic Type Breast Cancer.","authors":"Suk Jun Lee, Jung Min Park, Jee Hyun Ahn, Chan Seok Yoon, Seho Park","doi":"10.3349/ymj.2024.0408","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Rare special histologic types of breast cancer usually show a favorable prognosis but often has atypical features. Multigene tests (MGTs) in patients with special types of breast cancer have not been well studied. Therefore, we aimed to examine the association between MGTs and histopathology and to evaluate the prognosis of MGTs in patients with special types of breast cancer.</p><p><strong>Materials and methods: </strong>A total of 133 patients with special histologic types of breast cancer who underwent MGTs were selected from two institutions from 2013 to 2022. Special types were divided into favorable and unfavorable groups. The patients' clinicopathological characteristics and MGT results were compared, and disease-free survival (DFS) was analyzed.</p><p><strong>Results: </strong>The unfavorable group consisted of 76 (57.1%) patients and included more older patients, multiple tumors, grade II/III tumors, high-risk MGT results, and chemotherapy administration. High-risk MGTs were found in 16.5% of the total cohort. The unfavorable type tended to have high-risk MGTs, but multivariate analysis demonstrated that grade II/III tumors, low progesterone receptor expression, and high Ki-67 levels were associated with high-risk MGTs in special type breast carcinomas. MGTs were significantly associated with DFS, particularly in the unfavorable subgroup, in which no recurrence occurred among patients with low-risk MGTs.</p><p><strong>Conclusion: </strong>Unfavorable special types of breast cancer were more likely to have high-risk MGTs. The MGT result was a significant prognostic factor and could support decision-making for adjuvant therapies in patients with special histologic types of breast cancer.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 10","pages":"630-636"},"PeriodicalIF":2.8000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479197/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Yonsei Medical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3349/ymj.2024.0408","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Rare special histologic types of breast cancer usually show a favorable prognosis but often has atypical features. Multigene tests (MGTs) in patients with special types of breast cancer have not been well studied. Therefore, we aimed to examine the association between MGTs and histopathology and to evaluate the prognosis of MGTs in patients with special types of breast cancer.

Materials and methods: A total of 133 patients with special histologic types of breast cancer who underwent MGTs were selected from two institutions from 2013 to 2022. Special types were divided into favorable and unfavorable groups. The patients' clinicopathological characteristics and MGT results were compared, and disease-free survival (DFS) was analyzed.

Results: The unfavorable group consisted of 76 (57.1%) patients and included more older patients, multiple tumors, grade II/III tumors, high-risk MGT results, and chemotherapy administration. High-risk MGTs were found in 16.5% of the total cohort. The unfavorable type tended to have high-risk MGTs, but multivariate analysis demonstrated that grade II/III tumors, low progesterone receptor expression, and high Ki-67 levels were associated with high-risk MGTs in special type breast carcinomas. MGTs were significantly associated with DFS, particularly in the unfavorable subgroup, in which no recurrence occurred among patients with low-risk MGTs.

Conclusion: Unfavorable special types of breast cancer were more likely to have high-risk MGTs. The MGT result was a significant prognostic factor and could support decision-making for adjuvant therapies in patients with special histologic types of breast cancer.

多基因检测在特殊组织学类型乳腺癌患者中的临床应用
目的:罕见的特殊组织学类型的乳腺癌通常预后良好,但往往具有不典型的特征。特殊类型乳腺癌患者的多基因检测(mgt)尚未得到很好的研究。因此,我们旨在研究mgt与组织病理学之间的关系,并评估特殊类型乳腺癌患者的mgt预后。材料与方法:选取2013 - 2022年两所医院接受mgt治疗的特殊组织学类型乳腺癌患者133例。特殊类型分为有利组和不利组。比较两组患者的临床病理特征和MGT结果,并分析无病生存期(DFS)。结果:不良组包括76例(57.1%)患者,包括更多的老年患者、多发肿瘤、II/III级肿瘤、高危MGT结果和化疗。16.5%的队列中存在高危mgt。不利类型往往有高危mgt,但多因素分析表明,II/III级肿瘤、低孕酮受体表达和高Ki-67水平与特殊类型乳腺癌的高危mgt相关。mgt与DFS显著相关,特别是在不良亚组中,低风险mgt患者未发生复发。结论:不利的特殊类型乳腺癌更易发生高危mgt。MGT结果是一个重要的预后因素,可以支持特殊组织学类型乳腺癌患者辅助治疗的决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Yonsei Medical Journal
Yonsei Medical Journal 医学-医学:内科
CiteScore
4.50
自引率
0.00%
发文量
167
审稿时长
3 months
期刊介绍: The goal of the Yonsei Medical Journal (YMJ) is to publish high quality manuscripts dedicated to clinical or basic research. Any authors affiliated with an accredited biomedical institution may submit manuscripts of original articles, review articles, case reports, brief communications, and letters to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信